Ilia Buhtoiarov

Dr. Ilia Buhtoiarov

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
IBIlia Buhtoiarov
Ilia Buhtoiarov
ARAlexander L. Rakhmilevich
Alexander L. Rakhmilevich
LLLewis L Lanier
Lewis L Lanier
ERErik A Ranheim
Erik A Ranheim
PSPaul Sondel
Paul Sondel
Under different circumstances, tumors can inhibit or activate macrophage (Mφ) effector functions. We studied the mechanisms of tumor-Mφ interactions leading to Mφ activation. The results show that L5178Y mouse T cell lymphoma cells can prime naive mouse Mφ to subsequent LPS stimulation, resulting in increased NO production and antilymphoma effects in vitro. L5178Y cells, but not naive splenocytes, primed Mφ to ligation of TLR4 but not TLR9. L5178Y-primed Mφ incubated with LPS showed down-regulation of CD40 and up-regulation of NKG2D expression. Although L5178Y T cell lymphoma cells primed naive mouse Mφ, several other mouse and human cells lines failed to prime mouse Mφ. Neither L5178Y-conditioned supernatants nor coculture of Mφ and L5178Y cells in Transwells resulted in priming, indicating that direct L5178Y cell-Mφ contact was needed. Several receptor-ligand pairs are reciprocally expressed on Mφ and L5178Y cell membranes and can be potentially involved in Mφ priming. Of these, the CD40-CD154 pair played the most important role, as blocking the interaction of these molecules substantially reduced in vitro Mφ priming. Furthermore, simultaneous blocking of interactions between CD40-CD154, NKG2D-H60, and CD18-ICAM-1/2 led to complete abrogation of Mφ-mediated NO secretion and complete inhibition of Mφ-mediated tumor cell cytostasis. The priming of Mφ to LPS with L5178Y cells was also observed in vivo. These results suggest that contact with certain tumor cells via CD40, NKG2D, and CD18 molecules on the Mφ may facilitate Mφ-mediated antitumor immune surveillance.

7 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CWChunmeng Wang
Chunmeng Wang
XHXianglin Hu
Xianglin Hu
LYLingge Yang
Lingge Yang
YXYu Xu
Yu Xu
BZBiqiang Zheng
Biqiang Zheng
WYWangjun Yan
Wangjun Yan
Purpose: We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS). Patients and Methods: Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571). Results: Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%). Conclusions: Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.

26 January 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
IBIlia Buhtoiarov
Ilia Buhtoiarov
SMSudipto Mukherjee
Sudipto Mukherjee
TRTomas Radivoyevitch
Tomas Radivoyevitch
Langerhans cell histiocytosis (LCH) is a disorder with highly diverse clinical manifestations. We explored if age, sex, race, organ system involved, and therapy approaches determine patient survival in the era of modern treatments. LCH patient data reported to the Surveillance, Epidemiology, and End Results (SEER) program in 2010-2016 (n=1282; age: 0 to 100 y) was analyzed. Age-specific LCH incidence flattening to a low level suggests an age cutoff for pediatric patients of 20 years. The overall survival probability is lower for patients 21 to 100 years old (P<0.0001), irrespective of sex and race. The commonest sites involved in the 0- to 20-year age group were bone, skin, and bone marrow; this shifted to lung, bone, and skin as the commonest disease sites in patients 21 to 100 years of age. The treatments applied differed between age groups, as younger versus older patients were more likely to receive chemotherapy-based treatment (48.4% vs. 17%; P<0.0001). There also was a trend toward nonwhite versus white patients being less likely to receive chemotherapy-based treatment (31.7% vs. 38.2%; P=0.067). Whereas there are treatment disparities related to LCH patient age and perhaps race, patient age is the strongest predictor of survival, with patients 21 to 100 years of age with lung, lymph node, skin, and bone marrow disease having the worst outcomes (P<0.0001).

15 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
CFChristopher J. Forlenza
Christopher J. Forlenza
JRJaclyn Rosenzweig
Jaclyn Rosenzweig
AMAudrey Mauguen
Audrey Mauguen
IBIlia Buhtoiarov
Ilia Buhtoiarov
BCBranko Cuglievan
Branko Cuglievan
LGLisa Giulino-Roth
Lisa Giulino-Roth
Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/refractory HL.

18 May 2021 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
AZAnthony S. Zembillas
Anthony S. Zembillas
STStefanie M. Thomas
Stefanie M. Thomas
SRSeth J. Rotz
Seth J. Rotz
IBIlia Buhtoiarov
Ilia Buhtoiarov
RHRabi Hanna
Rabi Hanna
To the editor:Progress continues to be made regarding the treatment of children and adolescents with aggressive B-cell Non-Hodgkin Lymphoma (NHL). Recent data demonstrated patients with mature B-ce...

27 April 2025 in International Journal of Hematology
Verified
Journal Article
Open access
PDF file
IBIlia Buhtoiarov
Ilia Buhtoiarov
MMMilen Minkov
Milen Minkov
RVREZA VALI
REZA VALI
OAOussama Abla
Oussama Abla
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm with heterogeneous presentations. The discovery of BRAFV600E and other MAPK pathway mutations drastically transformed the treatment landscape, especially for high-risk LCH and CNS-LCH. While treatment strategies for children and adults are somewhat similar, response assessment methodologies remain highly dichotomized. Currently, separate treatment response criteria exist for children and adults, especially in therapeutic trials. Considering the rapid evolution of targeted MAPK-inhibitor therapies, along with ultrasensitive detection of minimal residual disease biomarkers (e.g., circulating BRAFV600E-encoding DNA) and sophisticated imaging tools (18F-FDG-PET and whole-body MRI), harmonization of response criteria in LCH is clearly warranted. The Histiocyte Society Global LCH Treatment Response Harmonization Task Force, a collaborative network of pediatric and adult LCH experts, is set to propose updated pediatric LCH treatment response criteria, which will also serve as the foundation for a universal response assessment tool for pediatric and adult LCH. In this review, we focus on the past, present, and likely future of response assessment in LCH patients, and discuss needs that remain unmet in the targeted therapy era.